Publications by authors named "Remi Forrat"

Claim this Profile
C
Controlled human infection trials: Legitimacy and conditions of implementation in France.
Anne-Laure Morin, Emmanuelle Blanc, Armelle Phalipon, Pierre-Henri Bertoye, Philippe Amiel, Remi Forrat

Therapie· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
Guy de Bruyn, Joyce Wang, Annie Purvis, Martin Sanchez Ruiz, Haritha Adhikarla, Remi Forrat

EClinicalMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.
Vasco Liberal, Remi Forrat, Cong Zhang, Charles Pan, Matthew Bonaparte

Microbiol Spectr· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
Stephen J Savarino, Matthew Bonaparte, Hao Wang, Gustavo H Dayan, Remi Forrat

Lancet Microbe· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Rémi Forrat, Gustavo H Dayan, Carlos A DiazGranados, Matthew Bonaparte, Thelma Laot

Clin Infect Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.
Carlos A DiazGranados, Edith Langevin, Matthew Bonaparte, Saranya Sridhar, Tifany Machabert, Rémi Forrat

Clin Infect Dis· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
Carlos A DiazGranados, Matthew Bonaparte, Hao Wang, Ming Zhu, Yaniv Lustig, Remi Forrat

Lancet Infect Dis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Gustavo H Dayan, Edith Langevin, Remi Forrat, Betzana Zambrano, Fernando Noriega

Vaccine· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Gustavo H Dayan, Edith Langevin, Peter B Gilbert, Yukun Wu, Zoe Moodie, Rémi Forrat

Vaccine· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Gustavo H Dayan, Juan-Francisco Galán-Herrera, Remi Forrat, Betzana Zambrano, Alain Bouckenooghe

Hum Vaccin Immunother· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
Sri Rezeki Hadinegoro, Jose Luis Arredondo-García, Maria Rosario Capeding, Carmen Deseda, Tawee Chotpitayasunondh, Remi Forrat

N Engl J Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.
Ming Qiao, David Shaw, Remi Forrat, Anh Wartel-Tram, Jean Lang

Am J Trop Med Hyg· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
Rosario Z Capeding, Imelda A Luna, Emily Bomasang, Socorro Lupisan, Jean Lang, Remi Forrat

Vaccine· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
Jorge Poo, Francisco Galan, Remi Forrat, Betzana Zambrano, Jean Lang

Pediatr Infect Dis J· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
Dennis Morrison, Thomas J Legg, Christopher W Billings, Remi Forrat, Sutee Yoksan

J Infect Dis· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Bruno Guy, Nolwenn Nougarede, Sarah Begue, Violette Sanchez, Nadia Souag, Remi Forrat

Vaccine· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Farshad Guirakhoo, Scott Kitchener, Dennis Morrison, Remi Forrat, Karen McCarthy

Hum Vaccin· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).
Violette Sanchez, Sophie Gimenez, Brian Tomlinson, Paul K S Chan, G Neil Thomas, Remi Forrat

Vaccine· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Scott Kitchener, Michael Nissen, Peter Nasveld, Remi Forrat, Sutee Yoksan

Vaccine· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Arunee Sabchareon, Jean Lang, Pornthep Chanthavanich, Sutee Yoksan, Remi Forrat

Pediatr Infect Dis J· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
Arunee Sabchareon, Jean Lang, Pornthep Chanthavanich, Sutee Yoksan, Rémi Forrat

Am J Trop Med Hyg· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis